Acurian Helped to Put a Sponsor at the Forefront of a Chronic Disease Market


Diabetes/Obesity / Type 2 Diabetes

This sponsor was in a crucial race in the diabetes space as it began phase III clinical trials for a new class of drug for type 2 diabetes.

They were also rolling into a crowded field of companies developing competitive compounds. The competition was stiff, but the race was worth winning. If their drug was approved, it could capture a major share of a market that was projected to nearly double to $50 billion by 2022.

Read More »